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ABSTRACT
Objective To establish an algorithm for first-trimester
combined screening for trisomy 21 with biochemical
testing from 7 to 14 weeks’ gestation and ultrasound
testing at 11–13 weeks.
Methods This was a multicenter study of 886 pregnancies
with trisomy 21 and 222 475 unaffected pregnancies with
measurements of free β-human chorionic gonadotropin
(β-hCG) and pregnancy-associated plasma protein-A
(PAPP-A) at 7–14 weeks’ gestation. Multiple regression
modeling of log-transformed marker values was used
to produce log multiples of the median (MoM) values
for PAPP-A and free β-hCG. The models included
terms for the center attended and the machine used
for biochemical analysis, gestational age, maternal
racial origin, maternal weight, smoking status and
method of conception. Bivariate Gaussian distributions
were fitted to log MoM PAPP-A and log MoM free
β-hCG in trisomy 21 and in unaffected pregnancies. In
each case the patient-specific risk for trisomy 21 was
estimated by multiplying the individual maternal age-
related risk with the likelihood ratio (LR) for fetal nuchal
translucency (NT) according to the mixture model and
the combined LR for maternal serum free β-hCG and
PAPP-A. Estimates of detection rates for trisomy 21 and
false-positive rates were calculated for combined screening
with measurements of NT at 12 weeks together with
measurements of free β-hCG and PAPP-A from 8 to
13 weeks.
Results In trisomy 21 pregnancies the mean log MoM
free β-hCG increased linearly with gestation between 7
and 14 weeks, whereas the relation between log MoM
PAPP-A and gestation was fitted by a quadratic equation
such that the maximum separation between trisomy 21
and unaffected pregnancies occurs at 9–10 weeks. At a
false-positive rate of 3% the detection rate of combined
screening at 12 weeks was 86% and this increased to
90% by biochemical testing at 9 weeks and ultrasound
scanning at 12 weeks. The detection rate increased to
92% by measuring PAPP-A at 9 weeks and free β-hCG
at the time of the scan at 12 weeks.
Conclusion The performance of first-trimester biochemi-
cal screening for trisomy 21 is best at 9–10 weeks rather
than at 7–8 or 11–14 weeks. Copyright  2010 ISUOG.
Published by John Wiley & Sons, Ltd.
INTRODUCTION
Effective screening for trisomy 21 is provided by a
combination of maternal age, fetal nuchal translucency
(NT) thickness, maternal serum free β-human chorionic
gonadotropin (β-hCG) and pregnancy-associated plasma
protein-A (PAPP-A) at around 11–13 weeks’ gestation1.
In the assessment of patient-specific risks for trisomy
21 the a-priori maternal age-related risk is multiplied
by likelihood ratios (LR), determined from the deviation
of the measured NT, free β-hCG and PAPP-A from the
respective expected levels.
A study of trisomy 21 cases and controls across the first
and second trimesters reported that there is a temporal
variation of biochemical markers in cases with trisomy
212,3. The temporal variation has two consequences for
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risk assessment: firstly, the classical constant median
separation models lead to inappropriate risk estimates
and there is a requirement for the use of variable median
separation models; and secondly, the improved clinical
discrimination of PAPP-A in earlier weeks may result in
better performance of biochemical screening from blood
sampling before 11 weeks. It was on the basis of this
early analysis of temporality that the previous Fetal
Medicine Foundation algorithms were based. Extensive
data on serum biochemistry at 11–13 weeks’ gestation
suggest that the performance of screening is better
when conducted at 11 than at 13 weeks. This occurs
because, although the separation between trisomy 21 and
unaffected pregnancies in serum free β-hCG increases
with gestation, the decreasing separation in PAPP-A levels
dominates4.
In this study we present the combined data from
four European centers containing 886 pregnancies with
trisomy 21 and about 220 000 unaffected pregnancies
with measurements of free β-hCG and PAPP-A at between
7 and 14 weeks’ gestation.
PATIENTS AND METHODS
This study is based on data on singleton pregnancies
from prospective first-trimester combined screening for
trisomy 21 at Center A (King’s College Hospital, London;
Fetal Medicine Centre, London), Center B (King George
Hospital, Goodmayes; Harold Wood Hospital, Romford;
Queens Hospital, Romford; Canterbury Hospital, Canter-
bury; William Harvey Hospital, Ashford; Queen Elizabeth
The Queen Mother’s Hospital, Margate; Homerton Uni-
versity Hospital, Hackney; St George’s Hospital, Tooting;
Epsom Hospital, Epsom; St Helier Hospital, Carshalton),
Center C (Aarhus University Hospital, Skejby, Denmark;
Regionshospitalet, Silkeborg; Regionshospitalet Randers
and Regionshospitalet, Viborg, Denmark) and Center
D (Fetal Medicine Centre, Nicosia, Cyprus and Alpha
Medical Diagnosis, Limassol, Cyprus). Karyotype results
and details on pregnancy outcomes were added into the
databases as soon as they became available. The data from
the UK on 96 803 unaffected pregnancies and 491 cases of
trisomy 21 and from Denmark on 10 243 unaffected and
97 trisomic pregnancies have been included in previous
publications4,5.
Prospective assessment of the risk for trisomy 21
was based on a combination of maternal age, fetal NT
thickness, and maternal serum PAPP-A and free β-hCG.
Serum samples collected at between 7 and 14 weeks’
gestation were analyzed to determine concentrations of
free β-hCG and PAPP-A using automated machines that
provide reproducible results within 30 min (Kryptor sys-
tem, Brahms AG, Berlin, Germany, or Delfia Express
system, Perkin Elmer, Waltham, MA, USA). Transabdom-
inal and, when necessary due to impaired visualization,
transvaginal, ultrasound NT measurements were per-
formed at around 11–13 weeks’ gestation to diagnose
any major fetal defects and for measurement of the fetal
crown–rump length (CRL) and NT thickness1. Gesta-
tional age was based on the CRL at the time of the NT
measurement6.
Maternal weight, measured at the time of serum
screening, demographic characteristics, ultrasonographic
measurements and biochemical results were recorded
in computer databases. Racial origin was assessed
by self-classification and included Caucasian, African,
South Asian (Indian, Pakistani, Bangladeshi), East
Asian (Chinese, Korean, Japanese) and mixed, which
mainly consisted of those of Caucasian and Afro-
Caribbean/African origin. Smoking status was based on
a self-completed questionnaire, and each woman was
classified as either a non-smoker or a smoker. The
mode of conception was either spontaneous or with
ovulation-induction drugs or assisted reproduction by
in-vitro fertilization. Missing data on smoking, ethnicity
or conception were accommodated by including a
‘missing’ factor for these variables. In a small proportion
of cases (1.5%) the maternal weight was missing and these
cases were allocated the mean of the women examined at
the same center.
Multiple regression modeling7 of log-transformed
marker values was used to produce log multiples of
the median (MoM) values for PAPP-A and free β-hCG.
The models included terms for the center attended and
machine used for biochemical analysis, gestational age,
maternal racial origin, maternal weight, smoking status
and method of conception. The mean log MoM values for
free β-hCG and PAPP-A in trisomy 21 were represented
as a linear and a quadratic function of gestational age.
Bivariate Gaussian distributions were fitted to log MoM
PAPP-A and log MoM free β-hCG in trisomy 21 and in
unaffected pregnancies. The adequacy of the fitted model
was assessed by inspecting histograms of the squared
Mahalanobis distances with the chi-squared distribution
superimposed. Gross outliers beyond the 99.99th centile
were removed.
In each case the patient-specific risk for trisomy 21
was estimated by multiplying the individual maternal
age-related risk by the LR for fetal NT according to
the mixture model8 and the combined LR for maternal
serum free β-hCG and PAPP-A. Crude, standardized and
model-based detection rates and false-positive rates were
obtained by taking the proportion of cases with risks
above a given risk threshold. The crude performance of
screening refers to the observed values in our dataset.
Standardized performance of screening was estimated
after adjustments to take into account the maternal
age distribution of pregnancies in England and Wales
in 2000–20029. Model-based estimates of screening
performance were derived by examining simulated data
from 500 000 unaffected pregnancies and 500 000 trisomy
21 pregnancies with the maternal age distribution of
pregnancies in England and Wales in 2000–2002, fetal
NT distributions according to the mixture model and log
MoM free β-hCG and log MoM PAPP-A distributions
as modeled from data in this study. Bootstrapping
techniques with 100 replications were used to estimate
Copyright  2010 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2010; 36: 404–411.
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95% confidence intervals for standardized detection rates.
Model-based estimates of detection rates for trisomy 21
and false-positive rates were also calculated for combined
screening by maternal age, fetal NT according to the
mixture model and serum free β-hCG and PAPP-A
for measurements of NT at 12 weeks together with
measurements of both free β-hCG and PAPP-A at 8,
9, 10, 11, 12 and 13 weeks as well as measurement of
free β-hCG and PAPP-A separately at 8, 9, 10, 11, 12 and
13 weeks.
RESULTS
The dataset included 222 475 euploid pregnancies and
886 trisomy 21 pregnancies. Details of maternal and
fetal characteristics are shown in Table 1. On the basis
of the maternal age distribution of the study population
the estimated number of trisomy 21 pregnancies, at the
time of screening, was 936 (95% prediction interval,
876–996).
Table 1 Characteristics of the study population
Parameter Value
Center
A 56 771 (25.4)
B 127 611 (57.1)
C 11 665 (5.2)
D 27 314 (12.2)
Maternal characteristics
Maternal age (years) 31.9 (27.7–35.8)
Maternal weight (kg) 65.0 (58.0–73.8)
Mode of conception
Spontaneous 217 352 (97.3)
In-vitro fertilization 5089 (2.3)
Ovulation-induction drugs 647 (0.3)
Not reported 273 (0.1)
Smoking status
Smoker 23 864 (10.7)
Non-smoker 182 043 (81.5)
Not reported 17 454 (7.8)
Ethnicity
Caucasian 189 819 (85.0)
African 11 043 (4.9)
South Asian 15 391 (6.9)
East Asian 1755 (0.8)
Mixed 3777 (1.7)
Not reported 1576 (0.7)
Gestational age when tested
7 weeks 283 (0.1)
8 weeks 6884 (3.1)
9 weeks 16 179 (7.2)
10 weeks 14 215 (6.4)
11 weeks 33 512(15.0)
12 weeks 98 011(43.9)
13 weeks 52 163 (23.4)
14 weeks 2114 (0.9)
Karyotype
Normal 222 475 (99.6)
Trisomy 21 886 (0.4)
Data are given as n (%) or median (25th –75th quartile).
Distribution of log MoM free β-hCG and PAPP-A in
unaffected and trisomy 21 pregnancies
In the unaffected pregnancies, the median gestational age-
related concentrations of free β-hCG and PAPP-A are
shown in Figure 1. The fitted regression relationships on
gestational age (GA, days) and maternal weight (Wt, kg)
in unaffected pregnancies were:
Log10 free β-hCG = −3.23998
− (0.0509672 × (GA − 77))
+ (0.000448023 × (GA − 77)2)
+ (3.151635 × log10 (GA − 40))
− (0.004502895 × (Wt − 69))
+ (0.00002674235 × (Wt − 69)2)
and
Log10 PAPP-A = 0.194961
+ (0.0284402 × (GA − 77))
− (0.000352202 × (GA − 77)2)
+ (0.0000124371 × (GA − 77)3)
− (0.00730782 × (Wt − 69))
+ (0.0000292028 × (Wt − 69)2).
Multiple regression analysis demonstrated significant
effects on the measured concentrations from the center
attended and machine used for biochemical analysis,
gestational age and maternal racial origin, weight,
smoking status and method of conception (Table 2).
The effects are similar to our previously published
estimates1. The MoM values for free β-hCG and PAPP-A
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Figure 1 Daily median concentrations with 95% CIs of
pregnancy-associated plasma protein-A (PAPP-A) ( ) and free
β-human chorionic gonadotropin (β-hCG) ( ).
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Table 2 Parameter estimates for the fitted Gaussian distributions for pregnancy-associated plasma protein-A (PAPP-A) and free β-human
chorionic gonadotropin (β-hCG) in euploid pregnancies in the study
PAPP-A Free β-hCG
Log scale Original scale Log scale Original scale
Parameter Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
Ethnicity
Caucasian 0.0000 1.0000 0.0000 1.000
African 0.1919 (0.1874 to 0.1963) 1.5555 (1.5396 to 1.5716) 0.0488 (0.0438 to 0.0538) 1.119 (1.106 to 1.132)
South Asian 0.0170 (0.0132 to 0.0209) 1.0400 (1.0308 to 1.0492) −0.0522 (−0.0565 to −0.0479) 0.887 (0.878 to 0.896)
East Asian 0.0371 (0.0265 to 0.0478) 1.0893 (1.0628 to 1.1164) 0.0189 (0.0070 to 0.0309) 1.045 (1.016 to 1.074)
Mixed 0.0249 (0.0176 to 0.0322) 1.0590 (1.0413 to 1.0771) −0.0081 (−0.0163 to 0.0001) 0.982 (0.963 to 1.000)
Smoking status
Non-smoker 0.0000 1.0000 0.0000 1.000
Smoker −0.0755 (−0.0786 to −0.0724) 0.8404 (0.8344 to 0.8465) −0.0159 (−0.0194 to −0.0124) 0.964 (0.956 to 0.972)
Mode of conception
Spontaneous 0.0000 1.0000 0.0000 1.000
IVF −0.0383 (−0.0447 to −0.0320) 0.9155 (0.9022 to 0.9290) 0.0283 (0.0212 to 0.0354) 1.067 (1.050 to 1.085)
Ovulation −0.0415 (−0.0591 to −0.0239) 0.9089 (0.8728 to 0.9465) 0.0218 (0.0020 to 0.0415) 1.051 (1.005 to 1.100)
drugs
Screening tool used
Kryptor 0.0000 1.0000 0.0000 1.000
Delfia Xpress −0.1191 (−0.1240 to −0.1143) 0.7601 (0.7517 to 0.7686) 0.0054 (0.0025 to 0.0082) 1.012 (1.006 to 1.019)
Center
A 0.0000 1.0000 0.0000 1.000
B 0.0065 (0.0039 to 0.0090) 1.0150 (1.0091 to 1.0210) 0.0054 (0.0025 to 0.0082) 1.012 (1.006 to 1.019)
C −0.0483 (−0.0542 to −0.0423) 0.8948 (0.8827 to 0.9072) 0.0351 (0.0284 to 0.0418) 1.084 (1.068 to 1.101)
D −0.0803 (−0.0861 to −0.0744) 0.8312 (0.8201 to 0.8425) −0.0358 (−0.0423 to −0.0292) 0.921 (0.907 to 0.935)
IVF, in-vitro fertilization.
Table 3 Estimated median multiples of the median (MoM) values
according to gestational age for free β-human chorionic
gonadotropin (β-hCG) and pregnancy-associated plasma protein-A
(PAPP-A) in trisomy 21 fetuses
Free β-hCG PAPP-A
Week n MoM (95% CI) MoM (95% CI)
8 26 1.2408 (0.9793–1.5723) 0.3967 (0.3168–0.4968)
9 46 1.3433 (1.1243–1.6050) 0.3476 (0.2935–0.4117)
10 41 1.3303 (1.1017–1.6063) 0.3699 (0.3092–0.4425)
11 116 1.8122 (1.6201–2.0272) 0.4145 (0.3726–0.4611)
12 417 1.9327 (1.8218–2.0504) 0.5057 (0.4781–0.5349)
13 231 2.0633 (1.9058–2.2339) 0.6158 (0.5710–0.6640)
14 9 2.1992 (1.4706–3.2886) 0.6449 (0.4399–0.9453)
at 8–13 weeks for maternal characteristics, method of
conception and for different centers and machines show
an adequate model fit (Figure 2).
Screening performance by maternal age, serum
biochemistry and nuchal translucency
In the trisomy 21 pregnancies, compared to unaffected
pregnancies, free β-hCG was increased and PAPP-A
was decreased (Figure 3). Estimated weekly medians
with 95% confidence intervals are presented in Table 3.
The quadratic term for log MoM PAPP-A was highly
significant (P = 0.0006) while that for log MoM free
β-hCG was not significant (P = 0.4). The standard
deviations of log MoM values for PAPP-A and free
β-hCG and the correlations between them are shown
in Table 4.
The fitted regression models for trisomy 21 were:
Log10 free β-hCG MoM = 0.2233838
+ (0.005761 × (GA − 77))
and
Log10 PAPP-A MoM = −0.419464
+ (0.00776061 × (GA − 77))
+ (0.000271947 × (GA − 77)2),
where GA is gestational age in days.
Screening performance by maternal age and serum
biochemistry
Standardized and model-based detection rates for trisomy
21 at fixed false-positive rates of 3 and 5% in screening
by maternal age and measurements of both free β-hCG
and PAPP-A at 8, 9, 10, 11, 12 and 13 weeks are shown
in Figure 4.
Model-based estimates of the performance of screening
for trisomy 21 by a combination of maternal age, fetal
NT at 12 weeks and measurements of both free β-hCG
and PAPP-A at 8, 9, 10, 11, 12 and 13 weeks as well as
Copyright  2010 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2010; 36: 404–411.
408 Wright et al.
Caucasian
Ovulation drugs
13Gestational age (weeks)
12
11
10
9
8
100–110
> 120Weight (kg)
110–120
90–100
80–90
70–80
60–70
50–60
< 50
African
South Asian
Racial origin
East Asian
Non-smokerSmoking status
Smoker
Spontaneous
IVFConception
DelfiaMachine
Kryptor
Source Center A
Center B
Center C
Center D
0.90 0.95 1.00 1.05 1.10
Median MoM (95% CI)
0.90 0.95 1.00 1.05 1.10
Median MoM (95% CI)
β-hCGPAPP-A
Figure 2 Median multiples of the median (MoM) with 95% CIs diagnostics for pregnancy-associated plasma protein-A (PAPP-A) and free
β-human chorionic gonadotropin (β-hCG) in chromosomally normal pregnancies. IVF, in-vitro fertilization.
measurement of free β-hCG and PAPP-A separately at 8,
9, 10, 11, 12 and 13 weeks are shown in Table 5 and
illustrated in Figure 5.
DISCUSSION
The findings of this large multicenter study demon-
strate the gestational age-related differences in serum
free β-hCG and PAPP-A between trisomy 21 and unaf-
fected pregnancies and provide estimates of the per-
formance of first-trimester screening utilizing different
strategies in terms of the selected gestation for mea-
surement of free β-hCG and PAPP-A. The key contri-
butions of the paper are firstly, improved regression
models for standardizing PAPP-A and free β-hCG for
gestation and weight that fit well across the range
of 7 to 14 weeks’ gestation; secondly, new regression
models for PAPP-A and free β-hCG MoM values in tri-
somy 21 pregnancies; and thirdly, demonstration that
in combined testing PAPP-A should not be measured
before 9 weeks because evidence suggests that the sep-
aration in log MoM PAPP-A between trisomy 21 and
unaffected pregnancies is maximum at 9–10 weeks and
narrows before this gestational age, and the spread in
log MoM values for PAPP-A increases very early in
gestation.
In unaffected pregnancies the maternal serum concen-
tration of PAPP-A increases with gestation between 7
and 14 weeks. Between 8 and 9 weeks, PAPP-A concen-
trations double and as gestation increases the rate of
increase drops to around 50% between weeks 12 and 13.
Free β-hCG increases to a maximum at around 9 weeks
and decreases thereafter.
The measured serum concentrations of these pla-
cental products were affected by maternal charac-
teristics, including racial origin, weight and method
of conception as well as the machine and reagents
used for the analysis. Consequently, we used multi-
ple regression analysis to estimate the effects of these
Copyright  2010 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2010; 36: 404–411.
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multiples of the median (MoM) according to gestational age in trisomy 21 fetuses with their regression lines and 95% CIs.
Table 4 Estimated distributional parameters for log multiples of
the median of pregnancy-associated plasma protein-A (PAPP-A)
and free β-human chorionic gonadotropin (β-hCG) in trisomy 21
and unaffected pregnancies
Standard deviation
GA when Correlation
tested PAPP-A Free β-hCG coefficient
Trisomy 21 pregnancies
8 weeks 0.2382 0.2197 0.1548
9 weeks 0.2490 0.2329 0.1535
10 weeks 0.2278 0.2631 0.1900
11 weeks 0.2528 0.2447 −0.0973
12 weeks 0.2392 0.2635 0.1234
13–14 weeks 0.2326 0.2464 0.1500
All 0.2388 0.2537 0.1054
Unaffected pregnancies
7–8 weeks 0.2456 0.2354 0.3788
9 weeks 0.2393 0.2366 0.3036
10 weeks 0.2349 0.2466 0.2388
11 weeks 0.2324 0.2584 0.2188
12 weeks 0.2221 0.2544 0.2153
13–14 weeks 0.2158 0.2542 0.2261
All 0.2251 0.2527 0.2312
GA, gestational age.
maternal variables in defining MoMs before compar-
ing affected and unaffected pregnancies. The effects
were similar to our previously published estimates4.
Another important finding highlighted by our data is
that, despite corrections for maternal characteristics
and reagents used for the analysis, there are variations
in the median MoMs of free β-hCG and PAPP-A
between different centers. Consequently, provision of
accurate patient-specific risks requires local adjustments
in each laboratory to achieve a median MoM value of
1.0 MoM.
In trisomy 21 pregnancies the mean log MoM free
β-hCG increased linearly with gestation between 8 and
13 weeks, as shown previously by Spencer et al.2,3. In
contrast, the relationship between log MoM PAPP-A and
gestation was fitted by a quadratic equation such that the
maximum separation between trisomy 21 and unaffected
pregnancies occurs at 9–10 weeks. As a consequence, the
performance of first-trimester biochemical screening was
best at 9–10 weeks rather than 7–8 or 11–14 weeks.
This is consistent with the results of a meta-analysis
of trisomy 21 pregnancies at 6–20 weeks that reported
a quadratic relationship for MoM PAPP-A with a
maximum separation between trisomy 21 and unaffected
pregnancies at 8–9 weeks10.
Effective first-trimester screening for trisomy 21
is provided by combining maternal age and serum
biochemistry with ultrasound examination for the
measurement of fetal NT thickness. However, the aim
of the first-trimester scan is not just to screen for
trisomy 21 but also to diagnose an increasing number
of fetal malformations, and in this respect the ability
Copyright  2010 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2010; 36: 404–411.
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Figure 4 Detection rates of trisomy 21 at fixed false-positive rates of 3% (a) and 5% (b) in screening by maternal age and measurements of
both free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A at 8, 9, 10, 11, 12 and 13 weeks’ gestation. - - - - ,
model-based rate; , empirical standardized rate (with 95% CIs).
Table 5 Model-based estimates of detection rates (%) for trisomy 21 at a fixed false-positive rate of 3% (2 and 5% given in parentheses) in
combined screening by maternal age, fetal nuchal translucency thickness at 12 weeks’ gestation and measurements of free
pregnancy-associated plasma protein-A (PAPP-A) and free β-human chorionic gonadotropin (β-hCG) at different gestational ages
Gestational age at free β-hCG test (weeks)
Gestational age at
PAPP-A test (weeks) 8 9 10 11 12 13
8 89 (85, 92) 89 (87, 92) 90 (87, 93) 91 (89, 94) 92 (90, 95) 93 (91, 95)
9 89 (86, 92) 90 (87, 93) 90 (88, 94) 91 (89, 94) 92 (90, 95) 94 (92, 96)
10 88 (85, 91) 89 (85, 92) 89 (87, 92) 91 (88, 93) 91 (89, 94) 92 (90, 95)
11 85 (82, 89) 86 (82, 90) 87 (84, 91) 88 (85, 92) 90 (87, 92) 91 (88, 94)
12 81 (77, 86) 82 (78, 86) 83 (80, 88) 85 (81, 88) 86 (83, 90) 88 (84, 91)
13 76 (71, 81) 77 (73, 83) 79 (74, 84) 80 (77, 85) 82 (78, 86) 84 (80, 88)
to visualize fetal anatomy is best at 12 weeks11. One
option in screening for trisomy 21 is to perform
biochemical testing and the ultrasound scan in the
same visit at 12 weeks, with estimated detection rates
of 86 and 90% at false positive rates of 3 and 5%,
respectively.
An alternative strategy for first-trimester combined
screening is for biochemical testing and ultrasound
scanning to be carried out in two separate visits, with
the first done at 9 weeks and the second at 12 weeks. For
false-positive rates of 3 and 5% the estimated detection
rates would be 90 and 93%, respectively. The improved
performance of such two-stage first-trimester screening
has already been reported from two previous prospective
studies5,12.
A third option would be to perform the scan at 12 weeks
and optimize the performance of biochemical testing by
measuring PAPP-A at 9 weeks and free β-hCG at the time
of the scan at 12 weeks or even later, with estimated
detection rates of 92 and 95% at respective false-positive
rates of 3 and 5%.
This study has demonstrated the potential advan-
tage, in terms of detection and false-positive rates,
of offering biochemical testing and the ultrasound
scan at different gestations within the first trimester.
The cost and patient acceptability of the alter-
native policies of such first-trimester testing will
depend on the existing infrastructure of antenatal
care, which will vary between different countries and
centers.
Copyright  2010 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2010; 36: 404–411.
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Figure 5 Model-based estimates of detection rate for trisomy 21 (a) and false-positive rate (b) at a fixed risk cut-off of 1 in 100 in combined
screening by maternal age, fetal nuchal translucency thickness at 12 weeks’ gestation and measurements of β-human chorionic gonadotropin
(β-hCG) and pregnancy-associated plasma protein-A (PAPP-A) at different gestational ages (GA) of 8, 9, 10, 11, 12 and 13 weeks.
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